phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer

Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared to a standard combination approach.

October 1, 2026


October 1 2026

September 30 2026

September 29 2026

September 28 2026

September 27 2026

September 25 2026

September 24 2026

September 23 2026

September 22 2026

September 21 2026

September 18 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy